Publicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (24)

2023

  1. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

  2. Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: Results from an international multi-institutional study

    International Journal of Gynecological Cancer

  3. Social media ambassadors and collaboration with OncoAlert: A European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 964-970

2022

  1. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

  2. SUCCOR cone study: conization before radical hysterectomy

    International Journal of Gynecological Cancer, Vol. 32, Núm. 2, pp. 117-124

  3. SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer

    International Journal of Gynecological Cancer, Vol. 32, Núm. 10, pp. 1236-1243

2021

  1. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

  2. Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study

    Gynecologic Oncology, Vol. 162, Núm. 3, pp. 590-598

  3. Radical hysterectomy in early cervical cancer in Europe: Characteristics, outcomes and evaluation of ESGO quality indicators

    International Journal of Gynecological Cancer, Vol. 31, Núm. 9, pp. 1212-1219

2020

  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  2. Patterns of recurrence after laparoscopic versus open abdominal radical hysterectomy in patients with cervical cancer: A propensity-matched analysis

    International Journal of Gynecological Cancer, Vol. 30, Núm. 7, pp. 987-992

  3. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer

    Gynecologic Oncology, Vol. 159, Núm. 1, pp. 142-149

  4. SUCCOR study: An international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer

    International Journal of Gynecological Cancer

2019

  1. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087

  2. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 343-357

  3. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  4. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

  5. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2018

  1. Complement C4d-specific antibodies for the diagnosis of lung cancer

    Oncotarget, Vol. 9, Núm. 5, pp. 6346-6355

2016

  1. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2516-2525